A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries. Richard G. Stearns of the U.S. District Court for the ...

A phase 2, randomized, double-blind trial (N=50) used oral semaglutide 3 mg/day then 7 mg/day, combining cue-reactivity testing with Timeline Follow-Back naturalistic drinking assessment and objective ...

Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...

Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.

Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve ...

Anosheh Afghahi, MD, explains how integrated health technologies can improve clinical trial matching, efficiency, and equity.

Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, ...

Congressional Republicans support enforcing diversity action plan requirements while distancing them from DEI rhetoric, amid uncertainty created by removal and altered reinstatement of FDA draft ...

Near-complete TTR stabilization with acoramidis translated into a moderate, clinically meaningful KCCQ-OS benefit at 30 months (LSM difference 9.9 points; P < .001). Treatment effects emerged early, ...

LATITUDE PsO 3001/3002 (n = 693; n = 1108) showed ~70% of patients achieving clear or almost clear skin at week 16 versus 11% to 13% on placebo and 30% to 32% on apremilast. Depth of response was ...

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at ...

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.